Refractory/relapsed (R/R) CD123-positive acute myeloid leukemia (AML) research hub

A Phase 1 Multicenter, Open Label, First-in-Human Dose Escalation Study of AFM28, a Bispecific ICE® that Targets CD123 and CD16A, in patients with CD123-Positive Relapsed/Refractory Acute Myeloid Leukemia

This early-stage study is testing a new medicine called AFM28 for people with a type of blood cancer called acute myeloid leukaemia (AML). It's for patients whose AML has come back or not responded to previous treatments. Researchers want to see if AFM28 is safe and what dose works best.